Related Experiment Video
Updated: Jun 14, 2026

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
Published on: November 5, 2014
LPAR4 mediates resistance to interferon-induced stress in soft tissue sarcoma
Jin-Fen Xiao1, Emily Y Ko1, Ashley Smith1
1Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract:
Soft tissue sarcomas are aggressive malignancies with limited responses to immunotherapy. Strategies that induce viral mimicry and type I interferon (IFN-I) signaling may enhance tumor immunogenicity but remain poorly explored in sarcoma. Here, we show that the CDK4/6 inhibitor abemaciclib triggers viral mimicry and robust IFN-I responses in sarcoma cells, leading to tumor growth suppression and remodeling of the tumor microenvironment toward an immune-permissive state. However, sarcoma cells activate resistance mechanisms that limit IFN-induced stress. We identify lysophosphatidic acid receptor 4 (LPAR4) as a key mediator of this adaptation. LPAR4 dampens IFN signaling, reduces oxidative stress, and promotes tumor cell survival under therapeutic pressure. Genetic silencing of LPAR4 enhances IFN responses, increases reactive oxygen species, and sensitizes sarcoma cells to apoptosis, resulting in delayed tumor growth. These findings identify LPAR4 as a central regulator of IFN-driven stress adaptation and a potential therapeutic target to enhance viral mimicry-based strategies in sarcoma.
Insights
The CDK4/6 inhibitor abemaciclib triggers viral mimicry and interferon responses in soft tissue sarcoma. Targeting LPAR4 enhances these effects, offering a new strategy to improve immunotherapy for sarcoma.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Soft tissue sarcomas are aggressive cancers with poor responses to immunotherapy.
- Viral mimicry and type I interferon (IFN-I) signaling can enhance anti-tumor immunity but are understudied in sarcoma.
Purpose of the Study:
- To investigate if CDK4/6 inhibitors can induce viral mimicry and IFN-I responses in sarcoma.
- To identify resistance mechanisms to IFN-I signaling in sarcoma.
- To explore LPAR4 as a therapeutic target to enhance immunotherapy in sarcoma.
Main Methods:
- Treatment of sarcoma cells with abemaciclib.
- Analysis of IFN-I signaling and viral mimicry.
- Genetic silencing of LPAR4.
- Assessment of tumor growth and microenvironment changes in vivo.
Main Results:
- Abemaciclib induced viral mimicry and IFN-I responses in sarcoma cells, suppressing tumor growth and promoting an immune-permissive microenvironment.
- Sarcoma cells developed resistance to IFN-I-induced stress via LPAR4.
- LPAR4 dampened IFN signaling and oxidative stress, promoting cell survival.
- Silencing LPAR4 enhanced IFN responses, increased reactive oxygen species, and sensitized sarcoma cells to apoptosis, delaying tumor growth.
Conclusions:
- Abemaciclib triggers beneficial anti-tumor immune responses in sarcoma by inducing viral mimicry and IFN-I signaling.
- LPAR4 is a key mediator of resistance to IFN-I-driven stress in sarcoma.
- Targeting LPAR4 may enhance the efficacy of viral mimicry-based immunotherapies for soft tissue sarcomas.
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Inhibitors of Viral Protein Synthesis

